Molecular screening of tumor samples for relapsed small cell lung cancer
Tests tumor and blood samples for genetic changes in adults with relapsed lung cancer.
Key facts
- Who runs it
- Samsung Medical Center
- Where
- Incheon, Jungbuk, Seongnam, Seoul, and Ulsan, South KoreaSee the 6 sites
- Trial code
- Registry title
- The Molecular Screening Study for the Umbrella Trial (SUKSES) in Relapsed Small Cell Lung Cancer Patients [SUKSES-S]
- Status
- Recruiting
- People taking part
- 797 people, planned
- Started
- 10 Jun 2016
- Expected to end
- Dec 2028
- Type of study
- Observational
- Treatments tested
- No treatment is included in this protocol.
- Record updated
- 12 August 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with small cell lung cancer. It only tests tumour tissue and blood for gene changes. No drug is given in this study.
- Age
- 20 years or older
- Sex
- All sexes can join
- Disease stage
- Small cell lung cancer confirmed by tissue or cell tests. ECOG performance status of 0 to 2.
- Earlier treatment
- Must be getting, or have had, platinum-based chemotherapy as first treatment. No more than two earlier chemotherapy regimens.
- Biomarker or test result
- Needs stored tumour tissue for gene testing, or agreement to a biopsy for it.
Main reasons for not taking part
- More than two earlier chemotherapy regimens for small cell lung cancer
- Pregnant or nursing women
- A second primary cancer, except some treated skin, cervical or other solid tumours
- Not having stored tissue and not agreeing to a biopsy
The registry criteria, word for word
Show all 9 criteriaShow less
Who can take part
- Provision of fully informed consent prior to any study specific procedures
- Patients must be ≥20 years of age
- Histologically or cytologically confirmed Small cell lung cancers
- ECOG performance status of 0 to 2
- Patients who are being treated or were treated with platinum-based chemotherapy as a first-line treatment
- Patients with available archival tissues for molecular analysis or patients who agreed with biopsy for molecular analysis
Who cannot take part
- More than two prior chemotherapy regimen for the treatment of small cell lung cancer
- Patients with second primary cancer, except: adequately treated non-melanoma skin cancer, curatively treated in-situ cancer of the cervix, or other solid tumours curatively treated with no evidence of disease for ≤2 years
- Pregnant or nursing women (women of reproductive potential have to agree to use an effective contraceptive method)
Where in South Korea
- Gachon University Gil Medical CenterIncheon, South KoreaContact: Se-Hoon Lee, MD,Ph.D.No longer taking part
- Chungbuk University HospitalJungbuk, South KoreaContact: Se-Hoon Lee, MD,Ph.D.No longer taking part
- Seoul National University Bundang HospitalSeongnam, South KoreaContact: Se-Hoon Lee, MD,Ph.D.No longer taking part
- Samsung Medical CenterSeoul, South KoreaContact: Se-Hoon Lee, M.D., Ph.D.Taking people
- VHS Medical CenterSeoul, South KoreaContact: Se-Hoon Lee, MD,Ph.D.No longer taking part
- Ulsan University HospitalUlsan, South KoreaContact: Se-Hoon Lee, MD,Ph.D.No longer taking part
About the trial
What the trial wants to find out
This protocol is a molecular screening protocol only. No drug intervention study will be included in this protocol. Based on the molecular profiling, patients may be eligible for drug intervention study of SUKSES trial.
Read full original descriptionShow less
This procedure can be performed during or after the first-line treatment. DNA will be extracted from the archived or fresh tissue and blood. NGS-based cancer panel and Nanostring CNV will be tested with DNA from tissue and/or blood.
Immunohistochemistry and FISH will be done by pathologists using archived or fresh tissue.
Tumor tissues (fresh or archival) will be analyzed using NGS-based cancer panel, nanostring CNV, immunohistochemistry and/or FISH.
Specific methods of each molecular tests will be defined with standard laboratory manual developed by pathologists.
The group in the trial
- Small cell lung cancers
To provide molecular characteristics of Small cell lung cancers to proceed SUKSES trial, To assess success rate of molecular profiling of Small cell lung cancers
Treatment: No treatment is included in this protocol.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- The Molecular Screening Study for the Umbrella Trial (SUKSES) in Relapsed Small Cell Lung Cancer Patients [SUKSES-S]
- Plain-language title
- Molecular screening of tumor samples for relapsed small cell lung cancerGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 12 August 2026